OPEN IN READ APP
JOURNAL ARTICLE
REVIEW

Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease

Sebastian Niezen, Humberto Diaz Del Castillo, Lumen A Mendez Castaner, Alessia Fornoni
Endocrinology, diabetes & metabolism 2019, 2 (3): e00072
31294086
Diabetic kidney disease (DKD) is the major contributor to the mortality and the financial burden of diabetes, accounting for approximately 50% of the cases of end-stage renal disease (ESRD) in the developed world. Several studies have already demonstrated that achieving blood pressure targets in DKD with agents blocking the renin-angiotensin system confer superior renoprotection when compared to other agents. However, the effects on renal outcomes of antihyperglycaemic agents in these patients have not been reported or studied broadly until recent years. The intent of this article is to review the available data on safety, efficacy, impact on renal outcomes and pathophysiology implications of the most utilized antihyperglycaemic agents in DKD/ESRD.

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Responses

Sort by: Most RecentHighest Rated

Nagaram Reddy

Presently we have very good selection of medications to use to control diabetic kidney diseases

-1

Trending Papers

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read
31294086
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"